Formerly known as Thermal technologies Inc, Hemedex, Inc. commercializes a platform patient monitoring technology conceived at the Massachusetts Institute of Technology (M.I.T.). The firm designs, develops and markets devices that measure tissue perfusion (i.e., blood flow at the capillary level). This technology addresses high clinical need situations in complex medical and surgical procedures. These complex procedures often involve compromised vasculature and other serious pathophysiology, which results in high rates of morbidity, delayed recuperation, poor patient outcome and higher, overall costs. The Company's patented technology will provide clinicians with a powerful tool to generate valuable prognostic data, which can provide an early warning of impending tissue ischemia and help target appropriate therapies rapidly and accurately. Hemedex's first product, the Bowman Perfusion Monitorâ¢, which has been used successfully in neurosurgical and organ transplantation clinical trials, provides a minimally invasive technique to accurately measure perfusion in small volumes of tissue continuously. Prior to the Bowman system, the capability to get continuous, real time perfusion measurements in absolute units (ml/100g-min) did not exist. These measurements are a long sought after and important parameter in understanding and managing critical medical situations. Data from the Bowman Perfusion Monitor⢠will help guide physicians in developing and implementing effective treatments quickly, which has the potential to improve patient outcome and lower costs. The Company's base proprietary technology in the clinical applications of thermal diffusion can be formulated to develop multiple products addressing unmet needs in many clinical areas such as neurosurgical monitoring, organ transplantation, cardiovascular monitoring, reconstructive surgery and oncology diagnosis, among othe
